The principal objective of the Biostatistics Core will be to provide project investigators a centralized resource for statistical expertise. Statistical issues will be addressed at all levels of investigation: from the design of experiments, to the maintenance of data quality, and the description and inferential statements made from the collected data. In support of this objective, the specific aims of the Biostatistics Core include: 1. To collaborate with project investigators in the formulation of hypotheses and hypothesis testing strategies, the design of experiments, Phase l/lltrials, and human subjects studies. To conduct and direct the statistical analyses of data generated by project investigators including: descriptive summary statistics, data modeling, experimental data inference and decision making. To insure that statistical principles associated with modeling nuisance or block effects, minimizing inference errors (Type I and II error) by correcting for multiple comparisons and multiple measures, randomization of conditions, and decreasing measurement error are employed in all studies. To collaborate with the Mouse Core director to ensure the above principles are used in obtaining reliable data from fully powered and unbiased designs. 5. To provide design expertise and oversight for the Phase l/llTrials. 6. To investigate or develop new statistical methodologies to directly address difficult data or design problems. To provide assistance in developing and implementing data management systems to allow investigators to effectively and efficiently manage and analyze their data,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095426-07
Application #
7682172
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
7
Fiscal Year
2008
Total Cost
$225,380
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539

Showing the most recent 10 out of 294 publications